ArriVent BioPharma, Inc. AVBP Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s deferred tax assets and other non-current assets?
- ArriVent BioPharma, Inc. (AVBP) reported deferred tax assets and other non-current assets of $156K in Q1 2026.
- How has ArriVent BioPharma, Inc.'s deferred tax assets and other non-current assets changed year-over-year?
- ArriVent BioPharma, Inc.'s deferred tax assets and other non-current assets decreased by 11.4% year-over-year, from $176K to $156K.
- What is the long-term trend for ArriVent BioPharma, Inc.'s deferred tax assets and other non-current assets?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s deferred tax assets and other non-current assets has grown at a 33.3% compound annual growth rate (CAGR), from $107K to $190K.